Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests tofacitinib for kids with arthritis

NCT ID NCT07211932

Disease control Sponsor: Consorci Sanitari de l'Alt Penedès i Garraf Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test the drug tofacitinib in 58 children with juvenile idiopathic arthritis (JIA) to see if it improves disease control after 12 months. Researchers will use real-world medical records to measure changes in arthritis activity. The goal is to find out if tofacitinib is a helpful treatment option for kids with JIA.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tofacitinib
What this could lead to
If it works, this could show that tofacitinib is an effective option for controlling juvenile idiopathic arthritis in children.
What could go wrong
This is a small, early-stage real-world study with only 58 participants, so results may not apply broadly. Tofacitinib can have side effects like increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 58 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with JIA

Ages

Up to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist. Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA. Age under 18 years at the time of the treatment indication with tofacitinib. Exclusion criteria: Participants diagnosed with any of the following conditions: Reactive arthritis Arthritis associated with inflammatory bowel disease Arthritis associated with another autoimmune disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile idiopathic arthritis (JIA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile idiopathic arthritis (JIA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Corporació Sanitària Parc Taulí de Sabadell

    Sabadell, Barcelona, Spain

  • Hospital Sant Joan de Déu Barcelona

    Barcelona, Barcelona, Spain

  • Hospital de Vilafranca

    Vilafranca del Penedès, Barceona, 08720, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.